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STUDY PROTOCOL Open Access
Fibrinogen Early In Severe Trauma studY
(FEISTY): study protocol for a randomised
controlled trial
James Winearls1,2,3*, Martin Wullschleger1,3, Elizabeth Wake1, Catherine Hurn2,4, Jeremy Furyk5, Glenn Ryan6,
Melita Trout7, James Walsham2,8, Anthony Holley2,4, Jeremy Cohen2,4, Megan Shuttleworth9, Wayne Dyer10,
Gerben Keijzers1,3,11, John F Fraser12, Jeffrey Presneill13 and Don Campbell1
Abstract
Background: Haemorrhage is a leading cause of death in severe trauma. Fibrinogen plays a critical role in
maintaining haemostasis in traumatic haemorrhage. Early fibrinogen replacement is recommended by several
international trauma guidelines using either fibrinogen concentrate (FC) or cryoprecipitate (Cryo). There is limited
evidence to support one product over the other with widespread geographic and institutional variation in practice.
This pilot trial is the first randomised controlled trial comparing FC to Cryo in traumatic haemorrhage.
Methods/design: The Fibrinogen Early In Severe Trauma studY (FEISTY) is an exploratory, multicentre, randomised
controlled trial comparing FC to Cryo for fibrinogen supplementation in traumatic haemorrhage. This trial will utilise
thromboelastometry (ROTEM®) to guide and dose fibrinogen supplementation. The trial will recruit 100 trauma
patients at four major trauma centres in Australia. Adult trauma patients with evidence of haemorrhage will be
enrolled on arrival in the trauma unit and randomised to receiving fibrinogen supplementation with either FC or
Cryo. The primary outcome is the differential time to fibrinogen supplementation. There are a number of
predetermined secondary outcomes including: effects of the intervention on plasma fibrinogen levels, feasibility
assessments and clinical outcomes including transfusion requirements and mortality.
Discussion: The optimal method for replacing fibrinogen in traumatic haemorrhage is fiercely debated. In this trial
the feasibility and efficacy of fibrinogen supplementation using FC will be compared to Cryo. The results of this
pilot study will facilitate the design of a larger trial with sufficient power to address patient-centred outcomes.
Trial registration: ClinicalTrials.gov, ID: NCT02745041. Registered 4 May 2016.
Keywords: Fibrinogen, Trauma, Haemorrhage, Cryoprecipitate, Fibrinogen concentrate, ROTEM®
Background
Despite advances in trauma management over the last
decade, haemorrhage in the setting of severe trauma
remains a leading cause of morbidity and mortality
[1, 2]. Death related to major haemorrhage is poten-
tially preventable and represents a target for mortality
reduction strategies. Traumatic haemorrhage is com-
plicated by a complex coagulopathy – trauma-induced
coagulopathy (TIC); the pathophysiological mechanisms
of which are incompletely understood [3, 4].
Fibrinogen plays a critical role in maintaining effective
haemostasis in traumatic haemorrhage and TIC [5, 6].
Fibrinogen is important in both primary haemostasis
through platelet aggregation and secondary haemostasis
where it is cleaved by thrombin to form fibrin [7, 8].
Fibrinogen is a glycoprotein synthesised in the liver
and the healthy adult has a plasma fibrinogen con-
centration of between 2 to 4 g/L. Hypofibrinogenae-
mia and increased fibrinogen breakdown are key
elements of TIC and fibrinogen is usually the first
factor to reach critically low levels in traumatic
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haemorrhage [9, 10]. Hypofibrinogenaemia after severe
trauma is associated with an increased risk of massive
transfusion and death [11–13]. It is postulated that early
fibrinogen replacement may assist in haemorrhage con-
trol, improve coagulopathy and reduce transfusion re-
quirements [13–15]. Recently published trauma guidelines
suggest that fibrinogen supplementation should occur in
the presence of plasma fibrinogen levels <1.5–2 g/L or
thromboelastometric signs of fibrinogen deficiency [16].
Major haemorrhage protocols (MHP) are a key com-
ponent of the damage control approach to the severely
bleeding trauma patient and the successful implemen-
tation of a MHP does improve outcomes [17, 18].
However, the ideal trauma MHP remains elusive, with
considerable geographical and institutional variation [19,
20]. The three most commonly utilised MHP are: (1)
high fixed-ratio blood product to packed red blood cell
transfusion (PRBC) transfusion, (2) targeted blood prod-
uct transfusion in response to viscoelastic haemostatic
assay (VHA) results and (3) a hybrid approach utilising a
high fixed ratio initially and subsequently transitioning
to a VHA-guided approach [21, 22].
Regardless of which approach is used fibrinogen can be
replaced with plasma, cryoprecipitate (Cryo) and fibrinogen
concentrate (FC) each containing different amounts of
fibrinogen; 2 g/L, 8–16 g/L and 20 g/L, respectively. The
low concentration of fibrinogen in plasma and the large
volumes required potentially make it unsuitable for dedi-
cated fibrinogen supplementation [23–25]. The RETIC trial
(NCT01545635) comparing plasma to factor concentrate-
based resuscitation has recently been terminated early after
an interim analysis revealed potential harm to patients ran-
domised to the plasma arm. Cryoprecipitate contains sub-
stantially higher concentrations of fibrinogen than plasma
and is widely accepted as the standard of care for fibrinogen
supplementation in severe haemorrhage [26]. However, its
use is not currently supported by high-level evidence [27].
The CRYOSTAT trial reported in 2015 that early fibrinogen
supplementation utilising Cryo was feasible and effectively
maintained fibrinogen levels in traumatic haemorrhage
[28]. The use of FC has a number of theoretical advantages
including: standard dose per vial, reduced volume, viral
inactivation, no requirement for ABO compatibility match-
ing, ease of reconstitution and administration. However, in
severe trauma there are no robust clinical trials to demon-
strate a survival or cost-effectiveness benefit compared to
Cryo [6, 25, 29].
A number of key questions regarding fibrinogen supple-
mentation in traumatic haemorrhage remain unanswered,
including: (1) What tests, if any should be utilised to guide
fibrinogen therapy? (2) What is the optimal product for
fibrinogen replacement? (3) What is the optimal dose of
fibrinogen? and (4) What is the impact of early fibrinogen
replacement on clinically important outcomes?
The objectives of this trial are to assess the feasibility
of early fibrinogen replacement utilising FC compared to
the use of Cryo in patients with traumatic haemorrhage
and viscoelastic evidence of hypofibrinogenaemia. We hy-
pothesise that fibrinogen replacement to reverse hypofibri-
nogenaemia in traumatic haemorrhage may be achieved
more rapidly, and with a more predictable dose response,
using FC compared to Cryo.
Methods/design
This is an investigator-initiated, pilot, multicentre, ran-
domised controlled trial (RCT) comparing FC to Cryo
for fibrinogen replacement in traumatic haemorrhage.
The trial will take place in four major trauma centres in
Queensland, Australia. The protocol adheres to the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Statement (Additional file 1).
Patients
The trial will enrol 100 adult (aged 18 years or older)
trauma patients judged by treating clinicians to have
clinically significant haemorrhage or potential for signifi-
cant transfusion requirements with an Assessment of
Blood Consumption Score (ABC Score) ≥2. The ABC
Score is a well-validated tool for the prediction of
massive transfusion, has been utilised in a recent civilian
trauma haemorrhage RCT and is simple to apply in the
complex multidisciplinary environment of major trauma
resuscitation [30–32]. See Table 1 for full inclusion and
exclusion criteria.
Randomisation
A computer-generated 1:1 block randomisation schedule
has been produced by a statistician independent to the
study, accommodating unequal recruitment across the
four initial sites together with the possibility of additional
Table 1 Inclusion and exclusion criteria
Inclusion criteria:
Adult (≥18 years) affected by trauma and
Judged to have significant haemorrhage or
Predicted to require significant transfusion with ABC Score ≥2
or by treating clinician judgment
Exclusion criteria:
Injury judged incompatible with survival
Previous fibrinogen administration this admission
Pretrauma centre dedicated fibrinogen replacement
Known objection to blood products
Known coagulation disorder
Pregnancy
Enrolment in competing study
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trial sites. Secure, password-protected web-based random-
isation will occur on patient arrival to a participating
hospital trauma unit once inclusion and exclusion criteria
have been assessed. Each patient will receive fibrinogen
supplementation comprising either protocol-directed FC
or Cryo therapy. Allocation concealment will be maintained
through to the conclusion of the web randomisation
process, but for practical and safety reasons, randomised
trial patients and their treating health care professionals will
not be blind to the trial intervention. Trial integrity will be
supported by maintenance of blinding for outcome asses-
sors and the trial statistician.
Intervention
After compliance with consent requirements and with
the treating clinician’s approval, patients will be rando-
mised to receive fibrinogen supplementation using either
FC (Riastap®, CSL Behring GmbH, Marburg, Germany)
or Cryo (Australian Red Cross Blood Service). The
requirement for fibrinogen supplementation will be
defined by a FIBTEM A5 (clot amplitude 5 min after
clot formation) ≤10 mm together with a clinical scenario
suggesting significant haemorrhage. The intervention
will be performed in randomised patients as soon as
possible after each FIBTEM threshold result becomes
known. Patients will remain in their allocated interven-
tion arm for the duration of their hospital admission up
to 30 days. Dosing of FC and Cryo will be guided by the
FIBTEM A5 result as per trial protocol (Fig. 1). FC will
be administered by intravenous injection and Cryo by
rapid intravenous infusion. Fibrinogen supplementation
will be continued throughout the resuscitation accord-
ing to protocol and as per the allocated intervention
arm (Fig. 1).
All other care received by trial patients will be pre-
scribed by the managing staff according to relevant local
hospital clinical and trauma guidelines that are based on
Emergency Management of Severe Trauma (EMST) or
Advanced Trauma Life Support (ATLS) principles. In all
centres a Damage Control Resuscitation (DCR) approach
to the management of severe trauma is standard practice;
with rapid identification and treatment of life-threatening
injuries, organ support and subsequent definitive injury
management once the patient has been stabilised [33]. In
patients with suspected haemorrhage the focus is geared
towards rapid identification and surgical or interventional
radiological control of haemorrhage. In all centres focused
bedside ultrasound scan (USS) and whole body ‘Trauma’
computed tomography (CT) imaging when haemo-
dynamic stability permits is standard of care. All centres
have a ‘Red Blanket’ protocol with rapid transfer directly
to the operating room (OR) for the haemodynamically
unstable and exsanguinating trauma patient. Concurrent
with haemorrhage control – haemostatic resuscitation
(HR) is employed, involving blood product transfusion,
correction of acidaemia, temperature control and organ
support in an attempt to maintain ‘normal’ physiology.
Trial endpoints
The primary outcome is the time interval in minutes
from FIBTEM analysis and clinical scenario suggesting
that fibrinogen supplementation is required to the com-
pletion of the first administration of fibrinogen supple-
mentation (FC or Cryo). It is aimed to administer the
FC intervention within 30 min of fibrinogen requirement
being identified. Consistent with the exploratory pilot
nature of this study, multiple hypothesis-generating out-
comes will be evaluated together with assessments of
process feasibility, including:
 Effects of fibrinogen supplementation (FC and Cryo)
on plasma fibrinogen
 Time to randomisation
 Time course of fibrinogen levels as measured by
FIBTEM and Clauss Fibrinogen (FibC)
 Transfusion requirements
 Clinically relevant thromboembolic complications
 Mortality at several time points including hospital
discharge and 90 days
Detailed data collection will occur for the first 7 days
of hospital admission and extended follow-up to 90 days
(see the SPIRIT figure in Fig. 2). See Table 2 for full
primary, secondary and feasibility outcomes.
Blood sampling
As previously stated the requirement for fibrinogen sup-
plementation will be guided by FIBTEM A5 (ROTEM®
Sigma) analysis. A number of other blood tests to assess
haemostasis will be performed at predefined time points
from admission to day 7 (Fig. 2). These include: ROTEM®
Sigma and Delta (FIBTEM, EXTEM, INTEM, HEPTEM),
Multiplate® (ADP, ASP, TRAP), TEG 6S (CK, CKH, CRT,
CFF), haemoglobin, platelet count, International Normal-
ised Ratio (INR), Activated Partial Thromboplastin Time
(APTT), Clauss Fibrinogen. Arterial blood gas analysis
(pH, lactate, base deficit, HCO3
−) will be performed on
admission and as clinically indicated. Likewise, blood
chemistry results assessing organ function will be per-
formed at the discretion of the treating clinical staff.
Sample size
The total pilot trial sample size of 100 patients (allocated
1:1 to FC or Cryo) was set based on estimated recruit-
ment rates across four sites and on available budget. An
anticipated 70% of participants will be male, consistent
with the usually observed sex ratio in severe trauma
patients. Using local data combined with the published
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interquartile range of time intervals in a recent trial of
early Cryo administration for major traumatic hae-
morrhage, an approximate standard deviation (SD) was
derived of 14 min for each treatment arm primary out-
come. Assuming this SD and normally distributed
time intervals, a trial with 100 evaluable patients,
equally divided between two groups, would have ap-
proximately 80% power to detect a difference of ±
8 min between mean FC and Cryo treatment intervals,
at a type 1 (alpha) error of 5%. With a fixed (n = 100)
total sample size, the SD of time intervals actually ob-
served will have a marked influence on trial power, as
summarised in Fig. 3. For example, an increase in each
group SD from 14 min to 30 min would increase the
detectable difference between mean responses of ex-
perimental and control subjects from 8 min to 17 min.
Additionally, 100 patients recruited across four sites
will enable accurate assessment of the feasibility out-
come measures which are an important component of
this pilot trial.
Fig. 1 Intervention and dosing strategy
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Statistical analysis
Data analyses will be performed with a coded binary
treatment indicator to preserve blinding to treatment
allocation until the trial report is finalised by the writing
committee. The trial primary and main secondary out-
comes will be reported using intention-to-treat analyses
based on all randomly assigned patients, except any who
withdraw consent for use of all trial data.
Baseline variables will be summarised using descriptive
statistics. The trial primary outcome and other time-to-
event outcomes will be displayed as Kaplan-Meier curves
and compared between treatments with Cox proportional
hazards regression including, as covariates, the trial site
stratification factor and patient age and sex. Sensitivity
analyses will be performed using unadjusted Cox models
which include a binary indicator of treatment as the only
covariate, and also using multivariable Cox models in-
cluding any other baseline covariates exhibiting subs-
tantial imbalance between randomisation arms. Lack of
proportionality in any Cox model on testing will result in
that outcome being assessed using a log-rank test and
summarised using the Kaplan-Meier estimated median
time to event [34]. Other secondary analyses, including
assessment of the differential proportion of thrombo-
embolic complications and mortality at specified time
points, will be compared using either chi-square or Fisher
exact tests, and also using logistic regression adjusting for
the same covariates used in the Cox models. Results will
be summarised using frequency tables, and risk ratios or
odds ratios as appropriate, with 95% confidence intervals.
Approximately normally distributed continuous variables
(either untransformed or following log or other normalising
transformation) will be compared using t tests, or otherwise
compared using nonparametric methods (Mann-Whitney).
The differential trajectory of fibrinogen levels over
time according to intervention will be assessed with
fibrinogen measurements at predefined time points for
each patient. Initial exploratory analyses will be con-
ducted using a ‘summary measures’ approach [35], com-
paring maximum and minimum fibrinogen levels within
individual patients during the acute resuscitation phase
and also the maximum fibrinogen in the postresus-
citation phase. Subsequently, univariable and adjusted
multivariable linear regression analyses will be used to
assess the differential effects on circulating fibrinogen
levels of treatment allocation using a generalised esti-
mating equation (GEE) approach with robust error esti-
mates to account for the within-subject correlation of
fibrinogen levels over time [36].
Data and Safety Monitoring Committee and interim
safety analysis
An independent Data and Safety Monitoring Committee
(DSMC) will conduct two equally spaced interim ana-
lyses, at one third (n = 33) and two thirds (n = 67) of the
time into trial recruitment, to assess the differential
Fig. 2 Fibrinogen Early In Severe Trauma studY (FEISTY) Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) flowchart
Winearls et al. Trials  (2017) 18:241 Page 5 of 11
proportions of all-cause hospital mortality (censored at
30 days for practical reasons) observed in intervention
(FC) compared with control (Cryo) patients.
These interim analyses will follow a group sequential plan
(Fig. 4) employing symmetrical, two-sided, Haybittle-Peto,
three-standard deviation thresholds to evaluate a standar-
dised test statistic (|Zk| ≥ 3) calculated from a normal
approximation to the discrete binomial difference observed
between treatment and control groups in mortality. Assum-
ing no early stopping, k = 3 planned analyses will occur,
with all-cause mortality assessed at n = 33, 67 and 100
patients (Fig. 4). Accounting for the type I error spent in
these two interim mortality analyses, and in the absence of
early stopping, a precise analysis of the trial primary out-
come at full recruitment could be conducted at p < 0.048
(|Z3| > 1.975) rather than the conventional statistical signifi-
cance level (p < 0.05; |Z1| > 1.96). However, in accord with
common practice with a small number of interim analyses
and symmetrical two-sided, three-standard deviation,
Haybittle-Peto thresholds, this trial’s primary analysis will
ignore the very small error spent conducting two interim
analyses, and evaluate the final primary trial outcome at the
conventional two-sided level of 0.05. The DSMC may
conduct additional interim analyses of mortality or other
outcomes at the committee’s discretion with adjustment to
the final level of significance (p value) if required.
Discussion
There is increasing recognition and substantial evidence
to support the importance of fibrinogen in effective clot
formation in traumatic haemorrhage. Hypofibrinogenae-
mia is associated with reduced clot strength, increased
transfusion requirements and worse outcomes [9, 12].
However, the optimal timing, method and dosing of
fibrinogen supplementation remains under debate.
The PROPPR trial has shown that early, high fixed-ratio
transfusion of blood products in traumatic haemorrhage is
beneficial in terms of achieving haemostasis and reducing
early death from exsanguination [31]. However, the early
and empiric delivery of specific fibrinogen-containing
products is not standard in the majority of fixed-ratio
MHP. A number of studies have reported that the fixed-
ratio MHP is ineffective in maintaining adequate fibrinogen
levels [24, 37]. Additionally there can be significant time de-
lays to Cryo transfusion and a large proportion of patients
do not receive Cryo as part of a fixed-ratio MHP [38, 39].
The CRYOSTAT trial has shown that it is feasible to utilise
Cryo empirically as part of a fixed-ratio MHP; however, the
median time to transfusion was still 60 min [28].
One of the major advantages in using FC is the rapid
time to delivery of fibrinogen supplementation. FC can
be stored in the trauma bay, rapidly reconstituted and
administered. The recently published FiiRST trial that
reports early FC use is feasible and increases plasma
Table 2 Outcome measures
Primary outcome measures:
1. (A) Time to administration of fibrinogen administration (FC or Cryo)
from time of ROTEM® analysis and clinical scenario suggesting that
fibrinogen supplementation is required
1. (B) Feasibility of administering FC within 30 min of ROTEM® and
clinical scenario suggesting that fibrinogen supplementation is required
2. Effects of fibrinogen supplementation (FC and Cryo) on fibrinogen
levels as measured by FIBTEM and Clauss Fibrinogen (FibC)
Secondary outcome measures:
1. Transfusion requirements (in number of units) of PRBC, FFP, FC, Cryo,
platelets, PCC at 4, 6, 12, 24 and 48 h
2. Duration of bleeding episode or time until surgical haemorrhage
control with no further coagulation factors
3. Duration of mechanical ventilation
4. Duration of ICU and hospital LOS
5. ROTEM® (Sigma and Delta), Multiplate®, FBC, INR, APTT, FibC analysis
at prespecified time points
6. Evaluation of EXTEM CT in response to fibrinogen supplementation
7. Adverse events: TACO, TRALI, Sepsis, MOF
8. Thromboembolic complications
9. All-cause mortality at 4, 6, 24 h and up to 90 days
Feasibility outcome measures:
1. Transfusion requirements (in number of units) of PRBC, FFP, FC, Cryo,
Platelets, PCC at 4, 6, 12, 24 and 48 h
2. Duration of bleeding episode or time until surgical haemorrhage
control with no further coagulation factors
3. Duration of mechanical ventilation
4. Duration of ICU and hospital LOS
5. ROTEM® (Sigma and Delta), Multiplate®, FBC, INR, APTT, FibC analysis
at prespecified time points
6. Evaluation of EXTEM CT in response to fibrinogen supplementation
7. Adverse events: TACO, TRALI, Sepsis, MOF
8. Thromboembolic complications
9. All cause mortality at 4, 6, 24 h and up to 90 days
Feasibility outcome measures:
1. Time to randomisation
2. FC and Cryo wastage
3. Proportion of patients with blood sampling at all prespecified
time points
4. Number of missed patients (eligible but not enrolled)
5. Randomisation errors
6. Protocol violations
APTT Activated Partial Thromboplastin Time, Cryo cryoprecipitate EXTEM CT
clotting time, FBC full blood count, FC fibrinogen concentrate, FFP fresh frozen
plasma, FibC Clauss Fibrinogen, ICU intensive care unit, INR International
Normalised ratio, LOS length of stay, MOF Multiple organ failure, PCC
Prothrombin complex concentrate, PRBC packed red blood cells, ROTEM®
thromboelastometry, TACO transfusion-associated circulatory overload,
TRALI transfusion-related acute lung injury
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fibrinogen levels during traumatic haemorrhage [40].
The recently completed, but not yet published, E-FIT trial
(ISRCTN67540073) investigated empiric fixed-dose FC
delivery in severe trauma in addition to standard MHPs,
with time to delivery of FC as the primary endpoint.
There is growing evidence to support the use of VHA
to rapidly guide targeted factor replacement in traumatic
haemorrhage but data from RCTs is limited [41, 42]. A
recent, single-centre RCT has reported significant reduc-
tions in blood product transfusion and improved
survival with a VHA-guided MHP [43]. Whilst the evi-
dence of a positive impact on mortality is equivocal, it is
clear that VHA can be used to rapidly and reliably iden-
tify coagulopathic trauma patients [44, 45]. The FIBTEM
assay can be utilised as a marker of TIC, predict massive
transfusion and it correlates well with standard labora-
tory measures of fibrinogen concentration [11, 46, 47].
The present study will utilise the FIBTEM assay to
identify patients with hypofibrinogenaemia and subse-
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Fig. 3 Sample size calculation
Stopping Boundaries – FC vs Cryo (HP k=3) 
Fig. 4 Interim analysis
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will be used to permit rapid intervention [48]. Each of the
trauma centres involved in the trial have varying degrees
of experience with VHA use in severe trauma [49]. This
trial will utilise the ROTEM Sigma device (an automated
cartridge-based system) to evaluate FIBTEM A5 and guide
subsequent fibrinogen replacement. The location of the
device either, at the point of care (POC) or in the labora-
tory environment, will depend on local logistical consider-
ations and will be decided by each individual centre.
Other blood product components will be administered as
per each individual trauma centre’s standard MHP. Specif-
ically, the use of tranexamic acid (TXA) as an intervention
for hyperfibrinolysis will be as per standard practice at
each individual trauma centre. The majority of Australian
trauma centres are currently participating in the rando-
mised controlled PATCH trial, investigating the prehospi-
tal use of TXA in severely injured trauma patients likely
to have TIC [50]. Co-enrolment in PATCH and FEISTY
has been agreed by both trial teams.
Dosing of fibrinogen utilising either Cryo or FC is con-
troversial with widespread variability in recommenda-
tions [6]. Current European Trauma Guidelines propose
FC 3–4 g or Cryo 50 mg/kg in severe traumatic haemor-
rhage [16]. Collins et al. describe a theoretical model of
fibrinogen dosing using plasma, Cryo and FC [51]. Al-
though not designed for clinical use it demonstrates the
different volumes of each product required to achieve a
desired increment in plasma fibrinogen. The recently
completed FIinTIC trial may provide further evidence;
this study randomised prehospital trauma patients to
receive FC or placebo, with admission fibrinogen levels
as the primary endpoint [52]. The currently recruiting
PRooF-ITH trial is randomising patients with traumatic
haemorrhage to receiving 60–70 mg/kg FC or placebo
on arrival in the trauma unit, with the primary end-
point being change in thromboelastography (TEG)
Functional Fibrinogen Amplitude at 15 min after inter-
vention [53]. Cryoprecipitate dosing is made more
complex by the varying fibrinogen content in each unit
and the variable dose response as measured by plasma
fibrinogen levels [27, 54, 55]. Published and institu-
tional data suggest that 1 g of fibrinogen (FC or Cryo)
will result in an increment of 1–2 mm in the FIBTEM
assay or 0.25 g/L using Clauss Fibrinogen [47, 56–58].
The dosing schedule (FC and Cryo) for our trial has
been designed in conjunction with our collaborators
from the Australian Red Cross Blood Service to provide
equitable dosing in both the FC and Cryo arms. To
achieve a 1-g dose of fibrinogen supplementation 3–4
units of whole blood Cryo will be required. The Cryo
dosing schedule will allow for approximately 250–
300 mg of fibrinogen per unit of whole blood Cryo and
will also allow blood banks to dispatch apheresis Cryo
when available.
A significant concern regarding the use of FC is the
potential for subsequent thromboembolic complications.
However, data from preclinical animal studies, a recently
published pharmacovigilance study, large observational
studies and a systematic review would suggest that there
is no increased risk of thromboembolic complications
associated with FC transfusion [59–62]. Additionally,
there is no evidence that even with large doses of
fibrinogen supplementation, plasma fibrinogen levels
exceed what would be expected subsequent to severe
trauma [28, 63].
A number of trials investigating FC use in non-
traumatic haemorrhage have recently been published.
The FIB-PPH trial reported no benefit to empiric FC
(versus placebo) in patients with clinically significant
postpartum haemorrhage; however, the mean plasma fi-
brinogen levels were >4 g/L [64]. The REPLACE trial in-
vestigating bleeding cardiac surgical patients also
reported no benefit to FC [65]. The ZEPLAST trial, also
in cardiac surgery, reported reduced bleeding and trans-
fusion requirements in patients treated with a fixed dose
of 6 g FC; however, subsequent analysis suggested that a
smaller dose would likely have yielded the same results
[66, 67]. These trials suggest that, based on clinical indi-
cations, it is difficult to predict those patients who will
benefit from supplemental fibrinogen and there is no
benefit in treating those who are not hypofibrinogenae-
mic. Therefore, it would seem logical to treat patients in
whom hypofibrinogenaemia is contributing to ongoing
haemorrhage and to dose-replace based on degree of
hypofibrinogenaemia.
There is an expanding observational evidence base to
support the use of FC in severe trauma, with recent
academic literature reporting: increased clot strength,
reduction in blood loss, reduced transfusion and mortal-
ity [14, 61, 68]. A recently published systematic review
found limited evidence comparing FC to Cryo and con-
cluded that it was not possible to recommend one prod-
uct over another [69]. It is imperative that robust and
clinically relevant trials are performed to investigate
fibrinogen replacement strategies in severe trauma be-
fore widespread practice changes are implemented with-
out a firm evidence base [70, 71].
The large doses of Cryo utilised in traumatic haemor-
rhage can put strain on local blood banks in supplying
requested units in a timely manner. Additionally, the size
of Australia introduces logistic challenges to the mainten-
ance of adequate Cryo stocks to individual hospital blood
banks. The use of a factor concentrate with a long shelf
life and that is easy to use is an attractive option but at this
time is not supported by good-quality evidence.
To our knowledge, FEISTY is the first RCT comparing
FC to Cryo for fibrinogen supplementation in severe trau-
matic haemorrhage. The trial expands on the currently
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utilised VHA-guided approach at the study sites, with
fibrinogen supplementation and dosing guided by FIB-
TEM analysis [72]. In addition to assessing the differential
time to effective fibrinogen supplementation, this trial will
provide information on appropriate dosing of fibrinogen
in traumatic haemorrhage. The results of this pilot trial in
conjunction with other ongoing trials will be used to
design a larger trial powered to address patient-centred
outcomes such as blood product transfusion requirements
and mortality.
Trial status
The trial commenced recruitment on 23 December 2016
with an estimated 15-month enrolment period. To date,
40/100 patients have been enrolled.
Additional file
Additional file 1: FEISTY SPIRIT Checklist (DOC 66 kb).
Abbreviations
A5: Amplitude of clot firmness 5 min after CT; ABC Score: Assessment of
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